Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Catherine who wrote (3729)	11/25/2000 3:18:18 PM
From: Gary Mohilner	Respond to of 5665

Catherine I think the key to IMGN is its technology. If you believe in the technology, you have to see it has the potential to go to levels that are far greater then anything MTSL has forecast. MTSL are no fools, they know this too, but they're trying to be conservative until they see something from the company that they can justify dramatically raising their target price for. I believe MTSL has seen their years of supporting IMGN prove itself, and they are slightly shocked by the success. Now they need to recognize that they were right all along, the technology's as good as they said it was, and the stock should rightfully go to much higher values. Perhaps they're waiting for another partnership, or another milestone, or both, but I believe they'll soon be calling IMGN a buy at prices under perhaps $50 with a target of perhaps $100. Furthermore, I think in 4 months or less they'll be raising the numbers again. Having said that, I also wouldn't be surprised if they also reduced the number of shares in each of their portfolios. This is not because they don't believe in the company, it's purely a matter of balance. Because of its growth, IMGN has become a dominant position in each portfolio, I believe they will take a profit and balance the portfolios. Gary